{"id":9871,"date":"2025-03-27T18:41:31","date_gmt":"2025-03-27T18:41:31","guid":{"rendered":"https:\/\/www.lupuscanada.org\/anifrolumab-impact-a-long-terme-sur-les-lldas-et-la-remission-chez-les-patients-atteints-de-lupus-resultats-des-essais-tulip\/"},"modified":"2025-03-27T18:43:47","modified_gmt":"2025-03-27T18:43:47","slug":"anifrolumab-impact-a-long-terme-sur-les-lldas-et-la-remission-chez-les-patients-atteints-de-lupus-resultats-des-essais-tulip","status":"publish","type":"post","link":"https:\/\/www.lupuscanada.org\/fr\/anifrolumab-impact-a-long-terme-sur-les-lldas-et-la-remission-chez-les-patients-atteints-de-lupus-resultats-des-essais-tulip\/","title":{"rendered":"Anifrolumab : impact \u00e0 long terme sur les LLDAS et la r\u00e9mission chez les patients atteints de lupus \u2013 R\u00e9sultats des essais TULIP"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb-29px||||false|false\u00a0\u00bb da_disable_devices=\u00a0\u00bboff|off|off\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb da_is_popup=\u00a0\u00bboff\u00a0\u00bb da_exit_intent=\u00a0\u00bboff\u00a0\u00bb da_has_close=\u00a0\u00bbon\u00a0\u00bb da_alt_close=\u00a0\u00bboff\u00a0\u00bb da_dark_close=\u00a0\u00bboff\u00a0\u00bb da_not_modal=\u00a0\u00bbon\u00a0\u00bb da_is_singular=\u00a0\u00bboff\u00a0\u00bb da_with_loader=\u00a0\u00bboff\u00a0\u00bb da_has_shadow=\u00a0\u00bbon\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_margin=\u00a0\u00bb-20px||||false|false\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_heading title=\u00a0\u00bbD\u00e9couvrez comment les essais TULIP ont d\u00e9montr\u00e9 que l\u2019anifrolumab am\u00e9liore consid\u00e9rablement les taux de lupus, de faible activit\u00e9 de la maladie (LLDAS) et de r\u00e9mission chez les patients atteints de LED.\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb title_text_align=\u00a0\u00bbcenter\u00a0\u00bb title_font_size=\u00a0\u00bb24px\u00a0\u00bb custom_margin=\u00a0\u00bb|48px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px||0px|false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb35px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p data-pm-slice=\"1 1 []\"><span style=\"font-size: 18px;\">L\u2019anifrolumab est l\u2019un des deux seuls traitements biologiques approuv\u00e9s pour les patients atteints de LED mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re.  <\/span>Cette \u00e9tude examine les avantages \u00e0 long terme de l\u2019ajout d\u2019anifrolumab au traitement standard pour les patients atteints de LED.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_image=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2024\/05\/Rectangle-1674.png\u00a0\u00bb custom_margin=\u00a0\u00bb20px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb30px||30px||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb||0px|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><span style=\"color: #ffffff;\"><span>Une r\u00e9cente analyse post-hoc des essais TULIP-1 et TULIP-2, suivie d\u2019une \u00e9tude de prolongation \u00e0 long terme, a \u00e9valu\u00e9 les effets de l\u2019anifrolumab, un anticorps monoclonal, sur l\u2019\u00e9tat de faible activit\u00e9 de la maladie (LLDAS) et la r\u00e9mission chez les patients atteints de lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED) mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re.<\/span><\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb28px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_heading title=\u00a0\u00bbPrincipales constatations\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb title_level=\u00a0\u00bbh4&Prime; title_font=\u00a0\u00bb||||||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb15px||||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|2px|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<ul>\n<li data-start=\"1064\" data-end=\"1222\" class=\"\">\n<p data-start=\"1066\" data-end=\"1222\" class=\"\"><strong data-start=\"1066\" data-end=\"1118\">L\u2019anifrolumab augmente les taux d\u2019AMPLDAS et de r\u00e9mission :<\/strong> L\u2019anifrolumab a significativement am\u00e9lior\u00e9 la probabilit\u00e9 d\u2019obtenir une LLDAS et une r\u00e9mission par rapport au placebo.<\/p>\n<\/li>\n<li data-start=\"1223\" data-end=\"1415\" class=\"\">\n<p data-start=\"1225\" data-end=\"1415\" class=\"\"><strong data-start=\"1225\" data-end=\"1248\">Avantages durables :<\/strong> Les patients recevant de l\u2019anifrolumab ont \u00e9t\u00e9 en mesure de maintenir ces \u00e9tats sur une p\u00e9riode plus longue, ce qui indique le potentiel du traitement \u00e0 am\u00e9liorer le contr\u00f4le de la maladie \u00e0 long terme.<\/p>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb8px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_heading title=\u00a0\u00bbImplications pour le traitement du LED\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb title_level=\u00a0\u00bbh4&Prime; title_font=\u00a0\u00bb||||||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb15px||||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|2px|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><span>Ces r\u00e9sultats sugg\u00e8rent que l\u2019anifrolumab, en combinaison avec le traitement standard, offre une option de traitement efficace pour les patients atteints de LED, am\u00e9liorant leurs chances de r\u00e9mission durable et une meilleure gestion de la maladie.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2025\/03\/LLDAS-and-remission-attainment-with-anifrolumab-LTE-Trial.pdf\u00a0\u00bb url_new_window=\u00a0\u00bbon\u00a0\u00bb button_text=\u00a0\u00bbVoir l\u2019\u00e9tude compl\u00e8te\u00a0\u00bb button_alignment=\u00a0\u00bbcenter\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_button=\u00a0\u00bbon\u00a0\u00bb button_text_size=\u00a0\u00bb18px\u00a0\u00bb button_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb button_bg_color=\u00a0\u00bb#6B198A\u00a0\u00bb custom_margin=\u00a0\u00bb38px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_button][et_pb_image src=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2025\/03\/LLDAS-and-remission-attainment-with-anifrolumab-LTE-Trial-pdf.jpg\u00a0\u00bb title_text=\u00a0\u00bbMILDDAS et obtention d\u2019une r\u00e9mission avec l\u2019essai LTE d\u2019anifrolumab\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2025\/03\/LLDAS-and-remission-attainment-with-anifrolumab-LTE-Trial.pdf\u00a0\u00bb url_new_window=\u00a0\u00bbon\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cette \u00e9tude examine les effets \u00e0 long terme de l\u2019anifrolumab sur l\u2019obtention de l\u2019\u00e9tat de faible activit\u00e9 de la maladie (LLDAS) et la r\u00e9mission chez les patients atteints de lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED). Les r\u00e9sultats des essais TULIP et leur prolongation \u00e0 long terme montrent que l\u2019anifrolumab augmente consid\u00e9rablement la probabilit\u00e9 d\u2019obtenir une r\u00e9mission LLDAS et DORIS par rapport au placebo, offrant l\u2019espoir d\u2019une am\u00e9lioration des r\u00e9sultats \u00e0 long terme pour les patients atteints de LED. <\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[92],"tags":[329,323,322,165,167,168,331,166,328,330],"topic":[113,115],"audience":[123,125,124],"class_list":["post-9871","post","type-post","status-publish","format-standard","hentry","category-article-fr","tag-activite-de-la-maladie","tag-poussees-de-lupus","tag-reaction-immunitaire","tag-recherche","tag-recherche-canadienne","tag-recherche-medicale","tag-remission-du-led","tag-sle-fr","tag-traitement-a-lanifrolumab","tag-traitement-du-lupus","topic-nouvelles-et-evenements","topic-recherche-et-essais-cliniques","audience-j-ai-le-lupus","audience-professionnel-de-la-sante","audience-une-personne-a-qui-je-tiens-a-le-lupus"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/9871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/comments?post=9871"}],"version-history":[{"count":0,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/9871\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/media?parent=9871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/categories?post=9871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/tags?post=9871"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/topic?post=9871"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/audience?post=9871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}